Lilly to invest $6 billion in Huntsville manufacturing hub
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
HYMPAVZI’s safety profile was generally favorable
The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Ipca Laboratories receives three observations from USFDA for API facility at Tarapur
Valorum will advance the commercialization and distribution of Armlupeg in the United States
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Subscribe To Our Newsletter & Stay Updated